Understanding gout treatment options: A clinical guide to flare control and long-term prevention

Understanding gout treatment options starts with two distinct objectives: controlling the pain and inflammation of an active gout attack, and lowering uric acid over time to reduce recurrent attacks and complications. The appropriate approach depends on attack severity, frequency of symptoms, kidney and cardiovascular health, gastrointestinal risk, liver function, and possible drug interactions. 1

How gout treatment is divided

Gout occurs when monosodium urate crystals accumulate in tissues and trigger inflammatory arthritis, often in the big toe but also in the ankles, knees, feet, hands, wrists, and elbows. A flare can develop suddenly, commonly overnight, and may cause severe pain, swelling, redness, and tenderness. Recurrent untreated attacks can affect more joints, last longer, and eventually contribute to tophi, which are masses of urate crystals in soft tissue or bone. 2

Clinical treatment therefore has two tracks. Anti-inflammatory medicines reduce pain and swelling during an attack, while urate-lowering therapy reduces the body’s urate burden and helps prevent future flares and joint damage. Medicines used for acute pain do not lower serum urate, so symptom relief alone does not address the underlying risk of recurrent crystal deposition. 9

Medicines for an acute gout flare

NSAIDs, colchicine, and corticosteroids are the main medication categories used for acute gout. NSAIDs include nonprescription ibuprofen and naproxen sodium, as well as prescription medicines such as indomethacin and celecoxib. Corticosteroids may be taken orally or injected, while colchicine is an oral anti-inflammatory option. The choice is individualized according to medical history and the number and severity of affected joints. 1

NSAIDs may be unsuitable for people with kidney disease, peptic-ulcer risk, or certain cardiovascular conditions. Colchicine can be affected by kidney or liver impairment and interacting medicines, making dose and safety review important. Corticosteroids may be considered when NSAIDs or colchicine are inappropriate, but the treatment decision still requires clinician assessment. Acetaminophen may help some less severe pain but does not replace anti-inflammatory treatment when substantial inflammation is present. 6

Long-term urate-lowering treatment

Long-term urate-lowering therapy is considered when gout attacks recur or when complications such as tophi develop. The American College of Rheumatology identifies allopurinol as the preferred first-line urate-lowering medicine, including for many people with moderate-to-severe chronic kidney disease. Treatment is generally started at a low dose and increased gradually while serum urate and adverse effects are monitored. 3

A commonly used treatment goal is a serum urate level below 6 milligrams per deciliter. A lower target may be considered in severe or tophaceous gout, although the target and monitoring schedule should be individualized. The purpose of this treat-to-target approach is to reduce the total urate burden, limit crystal formation, prevent flares, and protect joint function over time. 6

Alternatives and advanced therapies

Febuxostat is another xanthine oxidase inhibitor that lowers uric acid. It may be considered when allopurinol cannot be used or does not lower urate adequately, but cardiovascular history requires careful review. The U.S. Food and Drug Administration requires a boxed warning concerning an observed increased risk of cardiovascular death compared with allopurinol in a safety trial, so selection should involve a clinician’s assessment of individual risks and alternatives. 10

Pegloticase is an intravenous treatment reserved for adults with chronic gout that remains uncontrolled despite standard urate-lowering therapy. It is particularly relevant when frequent flares or tophi persist. Because it is an advanced therapy for severe, refractory disease rather than routine initial treatment, eligibility, monitoring, infusion-related concerns, and prior treatment response all affect whether it is appropriate. 8

Preventing flares when therapy begins

Starting or increasing urate-lowering therapy can temporarily destabilize urate deposits and provoke gout flares. For that reason, colchicine, an NSAID, or a corticosteroid is often prescribed for a limited preventive period during treatment initiation or dose escalation. This preventive strategy is separate from the long-term medicine that lowers serum urate and should be adjusted for kidney function, gastrointestinal risk, cardiovascular disease, and drug interactions. 3

Established urate-lowering therapy is commonly continued during an acute flare rather than stopped automatically, although prescription changes should be guided by the treating clinician. Stopping and restarting therapy without advice can complicate urate control and adherence. Regular follow-up helps determine whether the serum urate target has been reached and whether side effects, flare frequency, or changing health conditions require a revised plan. 4

Diagnosis, lifestyle, and safety decisions

A blood uric acid result alone cannot confirm or exclude gout. Levels may be high without symptoms, while some people with gout do not have a high level during an attack. When diagnosis is uncertain, joint-fluid examination can identify urate crystals under a microscope. Ultrasound, X-ray imaging, or dual-energy computed tomography may provide additional information or help rule out other causes of joint swelling. 1

Lifestyle measures can support medication by limiting alcohol, sugar-sweetened beverages, and high-purine foods such as organ meats, some seafood, red meat, and beer. Maintaining a healthy weight and staying hydrated may also form part of a broader management plan. These measures may not substitute for urate-lowering medicine when recurrent attacks, tophi, or other indications are present. Kidney disease, cardiovascular disease, ulcer risk, liver disease, and interacting medicines make individualized medical advice especially important. 2

Sources

1. Mayo Clinic, Gout: Diagnosis and treatment
2. Arthritis Foundation, Gout: Symptoms, Diagnosis, and Treatment
3. NCBI Bookshelf, Gout: StatPearls
4. Cleveland Clinic, Gout: What It Is, Symptoms and Treatment
5. Harvard Health, Gout medication to stop flare-ups
6. Arthritis Foundation, Treatments for Gout
7. Medscape, Gout and Pseudogout Treatment and Management
8. NCBI Bookshelf, Gout treatment review
9. Healio, Pharmacologic Urate-Lowering Therapy
10. U.S. Food and Drug Administration, Febuxostat cardiovascular safety warning